DNA Variants on Chromosome 9 May Be Associated with Increased Risk of IBS in Some Women

In April 2018, the journal Gastroenterology  reported that an international collaboration of researchers headed by the Karolinska Institutet in Sweden, has identified several DNA variants on Chromosome 9 that may be associated with higher risk of IBS in women, particularly IBS with constipation. This possible correlation was not found in men. The identified chromosomal regions

Gastrointestinal Society (Canada) Releases 2018 IBS Global Impact Report

In April 2018, in time for IBS Awareness Month, the Gastrointestinal Society in Canada released a 38 page 2018 IBS Global Impact Report, which is available for download on its website.  This report was funded and facilitated by the international pharmaceutical company Allergan, and overseen by a steering committee composed of Maura Corsetti, MD of

U.S. Food and Drug Administration (FDA) Approves Plecanatide (Trulance) for Use in IBS with Constipation, January 2018

In January 2018, plecanatide, also known by the brand name Trulance, and previously available in the United States for use in chronic idiopathic constipation, was approved by the U.S. Food and Drug Administration (FDA) for treatment of irritable bowel syndrome with constipation (IBS-C). See this link. https://www.healio.com/gastroenterology/irritable-bowel-syndrome/news/online/%7B0aa46942-f0d1-4b90-a703-335e5878dec4%7D/fda-approves-trulance-for-ibs-c Updated May 2018

Research Links Gut Microbiome Changes to Brain Structure in IBS

One of the interesting and groundbreaking articles presented this year at Digestive Disease Week, an annual international gastroenterology professional conference in May 2017 is a collaboration of 14 researchers from UCLA, Texas Children’s Microbiome Center and Baylor College of Medicine, and the Washington University School of Medicine in St, Louis, Missouri. The authors confirmed the

Health Canada Approves Eluxadoline (Viberzi)

On March 1, 2017, Health Canada, the national government agency responsible for approval of new medication, approved the use of eluxadoline, also known by the brand name Viberzi, for irritable bowel syndrome with diarrhea (IBS) in 75 mg. and 100 mg dosages. The detailed summary basis decision is available here. According to IBS Impact’s Canadian

Rome IV International Diagnostic Criteria Updated in 2016

Rome IV International Diagnostic Criteria Updated in 2016 International functional GI experts finalized Rome IV, the first major update to the Rome criteria since 2006, in December 2014 in Rome, Italy. Rome IV was published in the journal Gastroenterology in May 2016 and officially presented to the gastroenterology professional community at the Digestive Disease Week